Skip to main content
OpenTrials
Completed

NCT Number: NCT01989130

Evaluation of Immediate v. Delayed CT/NG Test for Treatment in the ED

The purpose of this study is to determine if immediate availability of GeneXpert® CT/NG test results reduces the overtreatment rate for ED patients with suspected gonorrhea or chlamydia and to assess changes in clinician management decisions with real-time test results.

Completed

Looking for future studies?

Notify Me

Key information

About this study

The investigators will conduct a randomized controlled trial in patients aged 18 and older where the treating clinician is ordering a CT/NG test. Clinicians will be approached by a research assistant while they are in the ED and asked whether a CT/NG swab will be ordered and if CT/NG is in the differential diagnosis. Then, potentially eligible patients will be approached and asked for consent to enroll. For patients that consent, simple randomization procedure (i.e. random number generator) will be used to assign patients to either immediate test results or delayed test results. Typically, in the ED these tests are ordered for diagnostic rather than screening purposes (symptoms of vaginal discharge, abdominal pain, etc). Patients will be randomized to batched testing with the Roche AMPLICOR CT/NG (standard of care, control group) or immediate testing of clinical specimens with Cepheid CT/NG with real-time result reporting (within 90 minutes) to the treating clinician in the ED. Patient interview and clinician survey will be conducted to ascertain perceptions of illness and the test. A follow up interview will be conducted with the patient to determine clinical and public health outcomes.

A validation of the Cepheid CT/NG test will be conducted against the hospital standard of care on </= 40 pilot participants. Pilot participants will be asked to provide 2 endocervical swabs and a urine specimen. All surveys and interviews will be conducted on pilot patients.

While many outcomes can be measured in this study, the investigators will power this study to reduce the overtreatment rate with antibiotics. Assuming a baseline overtreatment rate of 88% (# treated with antibiotics/# without disease), to reduce this rate by 50% (to 44%), at a power of 80% and alpha of 0.05, the investigators will need to enroll 42 patients (21 controls and 21 study patients) with negative tests. Given an estimated positive rate of 6%, and that approximately 50% of patients who receive these tests for any reason will be treated empirically with antibiotics, the investigators think that enrolling a total of 70 patients with full data (enrollment survey, clinician survey, and follow up survey) would be sufficient to identify trends with this subject matter. Due to the sensitive nature of the subject matter and the high percentages of lost-to-follow up with ED patients, the investigators estimate approximately 50% will have incomplete data. Therefore, the investigators request to enroll 150 patients in the study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • greater than 18 years
  • clinical suspicion of CT/NG
  • able to give informed consent
  • willingness to wait for test result

Exclusion criteria

  • less than 18 years
  • pregnancy
  • prisoners
  • unable to give informed consent

Treatment and study plan

Roche AMPLICOR CT/NG

Device

Cepheid Xpert CT/NG Test

Device

Primary outcomes

  1. Percentage of Participants Prescribed Antibiotic Treatment

    Time frame: one year

    Measurement of the number and type of antibiotics prescribed to CT/NG + v. CT/NG - in both groups

  2. Health Utilization

    Time frame: one year

    Number of participants with visits to healthcare facilities/providers and non-ED related medications purchased in 7-10 days after enrollment

  3. Healthcare Cost

    Time frame: one year

    To quantify the amount billed to insurance companies and out of pocket expenses for initial encounter

  4. Resolution of Symptoms

    Time frame: one year

    Number of patients that report having no symptoms 7 to 10 days after initial encounter

Sponsors and collaborators

Lead sponsor

George Washington University

Other

Collaborators

  • Cepheid

Registry information

Official study title

Evaluation of the Cepheid Xpert CT/NG For Management of STI in the ED: Immediate V. Delayed Test Results

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
Nov 20, 2013
Registry last updated
Aug 13, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.